A systematic review and meta-analysis on overall survival, failure-free survival and safety outcomes in patients with metastatic hormone-sensitive prostate cancer treated with new anti-androgens

Prostate cancer

Last Post by johan 4 years ago

1 Posts

1 Users

0 Reactions

2,260 Views

RSS

johan

(@j)

Joined: 8 years ago

Posts: 2292

Topic starter 26/11/2022 4:44 pm

https://journals.lww.com/anti-cancerdrugs/Abstract/9900/A_systematic_review_and_meta_analysis_on_overall.97.aspx

"The addition of either abiraterone, apalutamide, darolutamide or enzalutamide to ADT improves OS and failure-free survival in hormone-sensitive metastatic prostate cancer, albeit an increase in AEs."

Quote

54 Forums
1,040 Topics
7,327 Posts
24 Online
10.7 K Members

Forum Icons: Forum contains no unread posts Forum contains unread posts

Topic Icons: Not Replied Replied Active Hot Sticky Unapproved Solved Private Closed